News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
276,658 Results
Type
Article (14665)
Company Profile (294)
Press Release (261695)
Multimedia
Podcasts (67)
Webinars (11)
Section
Business (79733)
Career Advice (157)
Deals (13289)
Drug Delivery (38)
Drug Development (50609)
Employer Resources (31)
FDA (5796)
Job Trends (5158)
News (144855)
Policy (10066)
Tag
Academia (919)
Accelerated approval (9)
Adcomms (14)
Allergies (69)
Alliances (21763)
ALS (99)
Alzheimer's disease (964)
Antibody-drug conjugate (ADC) (175)
Approvals (5887)
Artificial intelligence (196)
Autoimmune disease (66)
Automation (9)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (77)
Biotechnology (231)
Bladder cancer (85)
Brain cancer (34)
Breast cancer (265)
Cancer (2491)
Cardiovascular disease (194)
Career advice (141)
Career pathing (4)
CAR-T (172)
CDC (5)
Cell therapy (465)
Cervical cancer (11)
Clinical research (42674)
Collaboration (874)
Company closure (2)
Compensation (466)
Complete response letters (31)
COVID-19 (1083)
CRISPR (74)
C-suite (379)
Cystic fibrosis (101)
Data (3182)
Denatured (13)
Depression (67)
Diabetes (218)
Diagnostics (1344)
Digital health (8)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (138)
Drug pricing (38)
Drug shortages (3)
Duchenne muscular dystrophy (181)
Earnings (31028)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (50501)
Executive appointments (597)
FDA (7147)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (5)
Frontotemporal dementia (14)
Funding (788)
Gene editing (147)
Generative AI (14)
Gene therapy (402)
GLP-1 (456)
Government (1126)
Grass and pollen (2)
Guidances (155)
Healthcare (6605)
HIV (12)
Huntington's disease (35)
IgA nephropathy (54)
Immunology and inflammation (152)
Immuno-oncology (10)
Indications (35)
Infectious disease (1175)
Inflammatory bowel disease (143)
Inflation Reduction Act (10)
Influenza (33)
Intellectual property (131)
Interviews (18)
IPO (7326)
IRA (12)
Job creations (866)
Job search strategy (129)
Kidney cancer (9)
Labor market (18)
Layoffs (236)
Leadership (7)
Legal (1395)
Liver cancer (38)
Longevity (8)
Lung cancer (365)
Lymphoma (169)
Machine learning (18)
Management (7)
Manufacturing (278)
MASH (108)
Medical device (2638)
Medtech (2643)
Mergers & acquisitions (6472)
Metabolic disorders (594)
Multiple sclerosis (85)
NASH (13)
Neurodegenerative disease (148)
Neuropsychiatric disorders (47)
Neuroscience (1684)
NextGen: Class of 2025 (2021)
Non-profit (858)
Now hiring (28)
Obesity (262)
Opinion (115)
Ovarian cancer (109)
Pain (80)
Pancreatic cancer (116)
Parkinson's disease (182)
Partnered (10)
Patents (242)
Patient recruitment (220)
Peanut (40)
People (26268)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (15085)
Phase II (19835)
Phase III (12543)
Pipeline (1721)
Policy (79)
Postmarket research (853)
Preclinical (6402)
Press Release (30)
Prostate cancer (119)
Psychedelics (47)
Radiopharmaceuticals (221)
Rare diseases (476)
Real estate (1439)
Recruiting (12)
Regulatory (9347)
Reports (19)
Research institute (953)
Resumes & cover letters (18)
Rett syndrome (13)
RNA editing (15)
RSV (16)
Schizophrenia (105)
Series A (146)
Series B (105)
Service/supplier (1)
Sickle cell disease (59)
Special edition (17)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1993)
State (1)
Stomach cancer (5)
Supply chain (28)
Tariffs (17)
The Weekly (53)
Vaccines (299)
Venture capital (44)
Weight loss (147)
Women's health (19)
Worklife (2)
Date
Today (103)
Last 7 days (391)
Last 30 days (1557)
Last 365 days (18296)
2025 (14816)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23358)
2019 (16225)
2018 (11742)
2017 (13747)
2016 (11839)
2015 (14350)
2014 (10395)
2013 (7486)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (152)
Alabama (58)
Alaska (2)
Arizona (60)
Arkansas (5)
Asia (17891)
Australia (3039)
California (5858)
Canada (1591)
China (602)
Colorado (206)
Connecticut (219)
Delaware (176)
Europe (38463)
Florida (731)
Georgia (180)
Hawaii (2)
Idaho (16)
Illinois (330)
India (24)
Indiana (137)
Iowa (8)
Japan (165)
Kansas (74)
Kentucky (7)
Louisiana (5)
Maine (11)
Maryland (638)
Massachusetts (4651)
Michigan (96)
Minnesota (214)
Mississippi (3)
Missouri (27)
Montana (14)
Nebraska (4)
Nevada (27)
New Hampshire (16)
New Jersey (1423)
New Mexico (12)
New York (1499)
North Carolina (726)
North Dakota (6)
Northern California (2759)
Ohio (153)
Oklahoma (11)
Oregon (22)
Pennsylvania (1093)
Puerto Rico (8)
Rhode Island (25)
South America (210)
South Carolina (6)
Southern California (2290)
Tennessee (32)
Texas (745)
United States (19598)
Utah (80)
Virginia (119)
Washington D.C. (36)
Washington State (490)
West Virginia (1)
Wisconsin (29)
276,658 Results for "seres therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025
·
1 min read
Press Releases
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
·
16 min read
Press Releases
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
September 23, 2025
·
8 min read
Press Releases
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
July 23, 2025
·
2 min read
Press Releases
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
October 15, 2025
·
6 min read
Press Releases
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
·
17 min read
Press Releases
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
May 28, 2025
·
7 min read
Press Releases
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
April 24, 2025
·
2 min read
Deals
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide Nestlé Health Science with full VOWST product and related intellectual property rights.
June 6, 2024
·
5 min read
Press Releases
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
April 30, 2025
·
3 min read
1 of 27,666
Next
